Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with type II diabetes regardless of duration of diagnosis with an admission blood glucose level between 140 mg/dL to 400 mg/dL will be included in the study.~* Other inclusion criteria are as follows:~  * age 18-80 years old~ * treated with diet alone~ * any combination of oral anti-diabetic agents or insulin treatment with any dosage before admission.~Exclusion Criteria:~* Hyperglycemia without a known history of diabetes~* H/o recent cardiac surgery (within 6 months)~* Impaired renal function (glomerular filtration rate less than 45)~* History of diabetic ketoacidosis~* Diabetes mellitus type 1~* Pregnancy~* Patients on steroid treatment~* Known hypopituitarism or adrenal insufficiency~* Known hypoglycemia of unawareness~* Length of stay \<48 h~* And severe liver disease and patent admitted in intensive care unit.~* Patients already received an insulin dose greater than 0.5 units/kg body weight after admission prior to initiation of study protocol will be excluded from the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NPH and regular insuline group (Type: EXPERIMENTAL): For the group receiving NPH and regular 2/3 and 1/3 formula will be followed. If Nil per os (NPO), patient will receive NPH twice daily but AM dose will equal to PM dose. Regular insulin given along with NPH will be held while patient is NPO. A correctional dose of regular insulin will be given for any blood glucose \>180 mg/dL. If subjects were not eating, they could also receive correctional doses of regular insulin. Correctional insulin could be given four times daily with meals or at bedtime.
- glargine and humalog group (Type: ACTIVE_COMPARATOR): Half of the total insulin dose will be given as glargine once daily, either in the AM or in the PM, depending on when the patient was enrolled. The other half of the total daily insulin dose was given as humalog; doses were divided equally between breakfast, lunch, and dinner. An additional correctional dose of humalog will be given for any blood glucose \>180 mg/dL. If subjects were not eating, they received glargine once daily and could also receive correctional doses of humalog. Correctional humalog could be given four times daily with meals or at bedtime.

Based on this trial design, predict the completion outcome and termination type (if applicable).